The federal government has split cannabis into two tracks. FDA-approved drug products containing marijuana and marijuana activity tied to a qualifying state-issued medical marijuana license under the new federal framework now occupy a different federal posture, while broader marijuana remains in Schedule I pending further proceedings.¹ That split is real, immediate, and carries tax, compliance, … Continue reading Why Cannabis Operators Can’t Afford to Ignore the Federal Rescheduling Details — And What You Must Do Now